InvestorsObserver
×
News Home

Should You Hold Exelixis, Inc. (EXEL) in Biotechnology Industry?

Monday, November 29, 2021 02:41 PM | InvestorsObserver Analysts

Mentioned in this article

Should You Hold Exelixis, Inc. (EXEL) in Biotechnology Industry?

A rating of 91 puts Exelixis, Inc. (EXEL) near the top of the Biotechnology industry according to InvestorsObserver. Exelixis, Inc.'s score of 91 means it scores higher than 91% of stocks in the industry. Exelixis, Inc. also received an overall rating of 60, putting it above 60% of all stocks. Biotechnology is ranked 87 out of the 148 industries.

Overall Score - 60
EXEL has an Overall Score of 60. Find out what this means to you and get the rest of the rankings on EXEL!

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 60 means the stock is more attractive than 60 percent of stocks. These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Exelixis, Inc. Stock Today?

Exelixis, Inc. (EXEL) stock has fallen -0.12% while the S&P 500 is up 1.59% as of 2:36 PM on Monday, Nov 29. EXEL is lower by -$0.02 from the previous closing price of $17.06 on volume of 933,060 shares. Over the past year the S&P 500 is up 28.88% while EXEL is lower by -11.06%. EXEL earned $0.51 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 33.27. Click Here to get the full Stock Report for Exelixis, Inc. stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App